Clotting Factor Product Administration and Same-day Occurrence of Thrombotic Events, as Recorded in a Large Healthcare Database During 2008-2013

Clotting Factor Product Administration and Same-day Occurrence of Thrombotic Events, as Recorded in a Large Healthcare Database During 2008-2013

Ekezue, BF (2015), Journal of Thrombosis and Haemostasis (Link to abstract)


This study utilized Blue Cross’ database (which processes all claims for people who hold that insurance) to see which patients were exposed to clotting factor products and how many of them had VTEs on the same day as the administration of the factor. They found significantly more VTEs in patients who did not have a congenital hemophilia who received factor. Although the numbers were smaller, this trend also held true in the pediatric age group. The highest risk was with increased age and with the use of Benefix or factor VIIa.


* This retrospective study seems to argue against the use of clotting factors off-label. Bear in mind, however, that many non-hemophilia patients receiving factors are likely to be sick and prone to clots for a variety of reasons – not the least of which is being on extracorporeal life support.